A Pilot Study Comparing the Effect of Flaxseed, Aromatase Inhibitor, and the Combination on Breast Tumor Biomarkers

REFERENCES

• Cianfrocca M and Goldstein LJ: Prognostic and predictive factors in early stage breast cancer. The Oncologist 9,606–616, 2004.
   PubMed Web of Science ®Google Scholar
• Howell A: New developments in the treatment of postmenopausal breast cancer. Trends Endocrinol Metab 16,420–428, 2005.
   PubMed Web of Science ®Google Scholar
• Kaufmann M and Rody A: Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy. J Cancer Res Clin Oncol 131,487–494, 2005.
   PubMed Web of Science ®Google Scholar
• Saladores PH, Precht JC, Schroth W, Brauch H, and Schwab M: Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer. Expert Rev Mol Diagn 13,349–365, 2013.
   PubMed Web of Science ®Google Scholar
• Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, et al.: Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 74,1286–1291, 1996.
   PubMed Web of Science ®Google Scholar
• Geisler J, Haynes B, Anker G, Dowsett M, and Lonning PE: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20,751–757, 2002.
   PubMed Web of Science ®Google Scholar
• Johannessen DC, Engan T, Di SE, Zurlo MG, Paolini J, et al.: Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 3,1101–1108, 1997.
   PubMed Web of Science ®Google Scholar
• Rakovitch E, Pignol JP, Chartier C, Ezer M, Verma S, et al.: Complementary and alternative medicine use is associated with an increased perception of breast cancer risk and death. Breast Cancer Res Treat 90,139–148, 2005.
   PubMed Web of Science ®Google Scholar
• Helyer LK, Chin S, Chui BK, Fitzgerald B, Verma S, et al.: The use of complementary and alternative medicines among patients with locally advanced breast cancer: a descriptive study. BMC Cancer 6,39–46, 2006.
   PubMedGoogle Scholar
• Gerber B, Scholz C, Reimer T, Briese V, and Janni W: Complementary and alternative therapeutic approaches in patients with early breast cancer: a systematic review. Breast Cancer Res Treat 95,199–209, 2006.
   PubMed Web of Science ®Google Scholar
• Navo MA, Phan J, Vaughan C, Palmer JL, Michaud L, et al.: An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies. J Clin Oncol 22,671–677, 2004.
   PubMed Web of Science ®Google Scholar
• Richardson MA, Sanders T, Palmer JL, Greisinger A, and Singletary SE: Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18,2505–2514, 2000.
   PubMed Web of Science ®Google Scholar
• Shen J, Andersen R, Albert PS, Wenger N, Glaspy J, et al.: Use of complementary/alternative therapies by women with advanced-stage breast cancer. BMC Complement Altern Med 2,8–14, 2002.
   PubMedGoogle Scholar
• Wang C, Makela T, Hase T, Adlercreutz H, and Kurzer MS: Lignans and flavonoids inhibit aromatase enzyme in human preadipocytes. J Steroid Biochem Mol Biol 50,205–212, 1994.
   PubMed Web of Science ®Google Scholar
• Thompson LU, Robb P, Serraino M, and Cheung F: Mammalian lignan production from various foods. Nutr Cancer 16,43–52, 1991.
   PubMed Web of Science ®Google Scholar
• Haggans CJ, Hutchins AM, Olson BA, Thomas W, Martini MC, et al.: Effect of flaxseed consumption on urinary estrogen metabolites in postmenopausal women. Nutr Cancer 33,188–195, 1999.
   PubMed Web of Science ®Google Scholar
• Hutchins AM, Martini MC, Olson BA, Thomas W, and Slavin JL: Flaxseed consumption influences endogenous hormone concentrations in postmenopausal women. Nutr Cancer 39,58–65, 2001.
   PubMed Web of Science ®Google Scholar
• Hutchins AM, Martini MC, Olson BA, Thomas W, and Slavin JL: Flaxseed influences urinary lignan excretion in a dose-dependent manner in postmenopausal women. Cancer Epidemiol Biomarkers Prev 9,1113–1118, 2000.
   PubMed Web of Science ®Google Scholar
• Chen J, Stavro PM, and Thompson LU: Dietary flaxseed inhibits human breast cancer growth and metastasis and downregulates expression of insulin-like growth factor and epidermal growth factor receptor. Nutr Cancer 43,187–192, 2002.
   PubMed Web of Science ®Google Scholar
• Dabrosin C, Chen J, Wang L, and Thompson LU: Flaxseed inhibits metastasis and decreases extracellular vascular endothelial growth factor in human breast cancer xenografts. Cancer Lett 185,31–37, 2002.
   PubMed Web of Science ®Google Scholar
• Brooks JD and Thompson LU: Mammalian lignans and genistein decrease the activities of aromatase and 17beta-hydroxysteroid dehydrogenase in MCF-7 cells. J Steroid Biochem Mol Biol 94,461–467, 2005.
   PubMed Web of Science ®Google Scholar
• Adlercreutz H, Bannwart C, Wahala K, Makela T, Brunow G, et al.: Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. J Steroid Biochem Mol Biol 44,147–153, 1993.
   PubMed Web of Science ®Google Scholar
• Chen J, Hui E, Ip T, and Thompson LU: Dietary flaxseed enhances the inhibitory effect of tamoxifen on the growth of estrogen-dependent human breast cancer (mcf-7) in nude mice. Clin Cancer Res 10,7703–7711, 2004.
   PubMed Web of Science ®Google Scholar
• Chen J, Tan KP, Ward WE, and Thompson LU: Exposure to flaxseed or its purified lignan during suckling inhibits chemically induced rat mammary tumorigenesis. Exp Biol Med (Maywood) 228,951–958, 2003.
   PubMed Web of Science ®Google Scholar
• Chen J and Thompson LU: Lignans and tamoxifen, alone or in combination, reduce human breast cancer cell adhesion, invasion and migration in vitro. Breast Cancer Res Treat 80,163–170, 2003.
   PubMed Web of Science ®Google Scholar
• Thompson LU, Rickard SE, Orcheson LJ, and Seidl MM: Flaxseed and its lignan and oil components reduce mammary tumor growth at a late stage of carcinogenesis. Carcinogenesis 17,1373–1376, 1996.
   PubMed Web of Science ®Google Scholar
• Wang L, Chen J, and Thompson LU: The inhibitory effect of flaxseed on the growth and metastasis of estrogen receptor negative human breast cancer xenograftsis attributed to both its lignan and oil components. Int J Cancer 116,793–798, 2005.
   PubMed Web of Science ®Google Scholar
• Thompson LU, Chen JM, Tong L, Strasser-Weippt K, and Goss PE: Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer. Clin Cancer Res 11,3828–3835, 2005.
   PubMed Web of Science ®Google Scholar
• Mark-Wahnefried W, Robertson CN, Walther PJ, Polascik TJ, Paulson DF, et al.: Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen. Urology 63,900–904, 2004.
   PubMed Web of Science ®Google Scholar
• Mark-Wahnefried W, Price DT, Polascik TJ, Robertson CN, Anderson EE, et al.: Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features. Urology 58,47–52, 2001.
   PubMed Web of Science ®Google Scholar
• Nesbitt PD, Lam Y, and Thompson LU: Human metabolism of mammalian lignan precursors in raw and processed flaxseed. Am J Clin Nutr 69,549–555, 1999.
   PubMed Web of Science ®Google Scholar
• Humfrey CD: Phytoestrogens and human health effects: weighing up the current evidence. Nat Toxins 6,51–59, 1998.
   PubMedGoogle Scholar
• Boucher BA, Cotterchio M, Curca IA, Kreiger N, Harris SA, et al.: Intake of phytoestrogen foods and supplements among women recently diagnosed with breast cancer in Ontario, Canada. Nutr Cancer 64,695–703, 2012.
   PubMed Web of Science ®Google Scholar
• Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, et al.: Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or Tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 11,951S–958S, 2005.
   PubMed Web of Science ®Google Scholar
• Trihia H, Murray S, Price K, Gelber RD, Golouh R, et al.: Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors—a surrogate marker? Cancer 97,1321–1331, 2003.
   PubMed Web of Science ®Google Scholar
• Clavel T, Henderson G, Alpert CA, Philippe C, Rigottier-Gois L, et al.: Intestinal bacterial communities that produce active estrogen-like compounds enterodiol and enterolactone in humans. Appl Environ Microbiol 71,6077–6085, 2005.
   PubMed Web of Science ®Google Scholar
• Clavel T, Borrmann D, Braune A, Dore J, and Blaut M: Occurrence and activity of human intestinal bacteria involved in the conversion of dietary lignans. Anaerobe 12,140–147, 2006.
   PubMed Web of Science ®Google Scholar
• Niemeyer HB, Honig D, Lange-Bohmer A, Jacobs E, Kulling SE, et al.: Oxidative metabolites of the mammalian lignans enterodiol and enterolactone in rat bile and urine. J Agric Food Chem 48,2910–2919, 2000.
   PubMed Web of Science ®Google Scholar
• Kelly SL and Kelly DE: Microbial cytochromes P450: biodiversity and biotechnology. Where do cytochromes P450 come from, what do they do and what can they do for us? Philos Trans R Soc Lond B Biol Sci 368,20120476, 2013.
   PubMed Web of Science ®Google Scholar
• Podust LM and Sherman DH: Diversity of P450 enzymes in the biosynthesis of natural products. Nat Prod Rep 29,1251–1266, 2012.
   PubMed Web of Science ®Google Scholar
• Miller KK, Al-Rayyan N, Ivanova MM, Mattingly KA, Ripp SL, et al.: DHEA metabolites activate estrogen receptors alpha and beta. Steroids 78,15–25, 2013.
   PubMed Web of Science ®Google Scholar
• Richter DU, Abarzua S, Chrobak M, Scholz C, Kuhn C, et al.: Effects of phytoestrogen extracts isolated from flax on estradiol production and ER/PR expression in MCF7 breast cancer cells. Anticancer Res 30,1695–1699, 2010.
   PubMed Web of Science ®Google Scholar
• Smollich M, Gotte M, Fischgrabe J, Radke I, Kiesel L, et al.: Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells. Anticancer Res 29,2167–2171, 2009.
   PubMed Web of Science ®Google Scholar
• Bershtein LM, Poroshina TE, Zimarina TS, Tsyrlina EV, Zhil’tsova EK, et al.: Expression of estrogen receptors-alpha and -beta in primary breast neoplasms and tumors exposed to neoadjuvant hormonal therapy. Bull Exp Biol Med 138,494–496, 2004.
   PubMed Web of Science ®Google Scholar
• Caldwell PH, Hamilton S, Tan A, and Craig JC: Strategies for increasing recruitment to randomised controlled trials: systematic review. PLoS Med 7,e1000368, 2010.
   PubMed Web of Science ®Google Scholar
• Demark-Wahnefried W, Polascik TJ, George SL, Switzer BR, Madden JF, et al.: Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev 17,3577–3587, 2008.
   PubMed Web of Science ®Google Scholar
• Demark-Wahnefried W, George SL, Switzer BR, Snyder DC, Madden JF, et al.: Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer. Clin Trials 5,262–272, 2008.
   PubMed Web of Science ®Google Scholar